Loading...
XHKG2359
Market cap21bUSD
Dec 20, Last price  
55.10HKD
1D
0.36%
1Q
29.65%
IPO
90.58%
Name

WuXi AppTec Co Ltd

Chart & Performance

D1W1MN
XHKG:2359 chart
P/E
15.36
P/S
3.69
EPS
3.37
Div Yield, %
1.69%
Shrs. gr., 5y
4.29%
Rev. gr., 5y
33.02%
Revenues
40.34b
+2.51%
4,139,780,7794,883,348,9616,116,130,8887,765,259,8569,613,683,59312,872,206,43716,535,431,46522,902,385,12939,354,777,80540,340,806,877
Net income
9.61b
+9.00%
461,500,977348,967,672974,980,3141,227,093,4792,260,523,1061,854,550,9342,960,235,4955,097,155,2838,813,713,0339,606,749,135
CFO
13.39b
+26.10%
712,548,594738,595,7771,756,793,4171,793,610,2741,640,427,7642,916,032,3123,973,728,2224,589,288,73310,616,029,91613,386,911,778
Dividend
Jun 17, 20241.087 HKD/sh
Earnings
Jun 12, 2025

Profile

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
URL
https://www.wuxiapptec.com/
IPO date
May 08, 2018
Employees
41,296
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
40,340,807
2.51%
39,354,778
71.84%
22,902,385
38.50%
Cost of revenue
26,262,987
27,949,979
16,999,621
Unusual Expense (Income)
NOPBT
14,077,820
11,404,798
5,902,765
NOPBT Margin
34.90%
28.98%
25.77%
Operating Taxes
2,131,731
1,715,866
879,662
Tax Rate
15.14%
15.05%
14.90%
NOPAT
11,946,089
9,688,932
5,023,103
Net income
9,606,749
9.00%
8,813,713
72.91%
5,097,155
72.19%
Dividends
(2,649,084)
(1,529,442)
(889,580)
Dividend yield
1.23%
0.60%
0.25%
Proceeds from repurchase of equity
(1,498,414)
(1,676,529)
BB yield
0.69%
0.48%
Debt
Debt current
3,667,060
4,101,547
2,657,904
Long-term debt
2,884,121
2,748,714
2,645,097
Deferred revenue
910,922
770,601
Other long-term liabilities
1,610,039
148,013
664,487
Net debt
(18,851,299)
(11,292,742)
(12,328,174)
Cash flow
Cash from operating activities
13,386,912
10,616,030
4,589,289
CAPEX
(5,516,559)
Cash from investing activities
(7,955,623)
Cash from financing activities
(3,722,647)
FCF
7,861,098
(278,230)
(1,669,778)
Balance
Cash
14,560,841
7,987,741
8,766,061
Long term investments
10,841,639
10,155,261
8,865,114
Excess cash
23,385,440
16,175,263
16,486,056
Stockholders' equity
29,137,315
22,433,721
15,347,858
Invested Capital
39,194,673
36,794,737
28,592,705
ROIC
31.44%
29.64%
17.75%
ROCE
22.50%
21.35%
13.34%
EV
Common stock shares outstanding
2,965,046
3,125,430
2,946,333
Price
72.76
-10.17%
81.00
-31.69%
118.58
5.62%
Market cap
215,736,749
-14.78%
253,159,842
-27.54%
349,376,112
9.50%
EV
197,280,441
242,843,246
338,510,895
EBITDA
16,361,390
13,098,278
7,188,525
EV/EBITDA
12.06
18.54
47.09
Interest
120,283
159,837
128,333
Interest/NOPBT
0.85%
1.40%
2.17%